Scarica l'app Stockscreener
22.02
8.86%
-2.14
Pre-mercato:
21.56
-0.46
-2.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché HIMS Giù?
Forum
Previsione
Precedente Chiudi:
$24.16
Aprire:
$23.95
Volume 24 ore:
33.06M
Relative Volume:
1.08
Capitalizzazione di mercato:
$5.02B
Reddito:
$2.35B
Utile/perdita netta:
$128.37M
Rapporto P/E:
42.18
EPS:
0.5221
Flusso di cassa netto:
$57.42M
1 W Prestazione:
-11.10%
1M Prestazione:
+40.88%
6M Prestazione:
-61.92%
1 anno Prestazione:
-33.01%
Intervallo 1D:
$21.70
$24.25
Intervallo di 1 settimana:
$21.70
$25.24
Portata 52W:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Nome
Hims Hers Health Inc
Settore
Telefono
415-851-0195
Indirizzo
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
22.02 | 5.02B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
17.83 | 56.33B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
115.67 | 48.83B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
10.07 | 44.83B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
28.73 | 33.46B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
524.28 | 22.98B | 3.18B | 1.33B | 1.04B | 27.90 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-10 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Aggiornamento | Citigroup | Sell → Neutral |
| 2026-03-09 | Aggiornamento | Needham | Hold → Buy |
| 2026-02-24 | Downgrade | BTIG Research | Buy → Neutral |
| 2026-01-12 | Iniziato | Evercore ISI | In-line |
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-21 | Iniziato | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Downgrade | Needham | Buy → Hold |
| 2025-06-04 | Reiterato | Needham | Buy |
| 2025-04-29 | Downgrade | TD Cowen | Buy → Hold |
| 2025-02-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Downgrade | Citigroup | Neutral → Sell |
| 2025-01-07 | Iniziato | BTIG Research | Buy |
| 2024-12-17 | Iniziato | Morgan Stanley | Overweight |
| 2024-11-14 | Downgrade | BofA Securities | Buy → Underperform |
| 2024-08-22 | Iniziato | Needham | Buy |
| 2024-08-09 | Downgrade | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Downgrade | Citigroup | Buy → Neutral |
| 2024-04-16 | Downgrade | Jefferies | Buy → Hold |
| 2024-04-10 | Iniziato | Canaccord Genuity | Buy |
| 2024-02-28 | Aggiornamento | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Iniziato | Leerink Partners | Market Perform |
| 2023-12-07 | Iniziato | Imperial Capital | In-line |
| 2023-07-28 | Iniziato | TD Cowen | Outperform |
| 2023-04-11 | Iniziato | Robert W. Baird | Neutral |
| 2023-02-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2022-11-08 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Iniziato | Truist | Hold |
| 2022-07-15 | Iniziato | SVB Leerink | Underperform |
| 2022-04-14 | Iniziato | Guggenheim | Buy |
| 2022-04-01 | Ripresa | Credit Suisse | Outperform |
| 2022-03-10 | Iniziato | Deutsche Bank | Hold |
| 2021-12-02 | Iniziato | Jefferies | Hold |
| 2021-11-11 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Iniziato | BofA Securities | Neutral |
| 2021-05-20 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Iniziato | Truist | Hold |
| 2021-03-09 | Iniziato | Credit Suisse | Neutral |
| 2021-03-02 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-02-17 | Iniziato | Citigroup | Neutral |
| 2021-02-12 | Iniziato | Piper Sandler | Neutral |
| 2021-02-08 | Iniziato | Tigress Financial | Buy |
Mostra tutto
Hims Hers Health Inc Borsa (HIMS) Ultime notizie
Canaccord Lowers Hims & Hers Health, Inc. (HIMS) Price Target Patent Amid Dispute and FDA Scrutiny - MSN
Hims & Hers (HIMS) soars 10.3% on analyst upgrades, new deal - MSN
Hims & Hers (HIMS) tumbles 8.86% on market bloodbath, profit-taking - MSN
Hims & Hers (HIMS) Tumbles 8.86% on Market Bloodbath, Profit-Taking - Insider Monkey
Hims & Hers Health Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Hims & Hers Health, Inc.HIMS - Morningstar
Does Hims & Hers (HIMS) Novo Nordisk Deal Quietly Redraw Its Risk Reward Profile? - Yahoo Finance
Hims Says Failed Wegovy Collab Doesn't Merit Investor Suit - Law360
Hims & Hers stock falls as technical resistance weighs and buyers lose steam near $24 - Traders Union
Hims & Hers Elevates Technology-Driven Healthcare Accessibility - MSN
Investor relations - HIMS Investor Relations
Hims & Hers Health stock: Daily momentum and support levels drive a 3.41% advance - Traders Union
Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy - Benzinga
Buying pressure lifts Hims & Hers Health stock higher in today's trading - Traders Union
Understanding Momentum Shifts in (HIMS) - Stock Traders Daily
Barclays raises PT on Hims & Hers Health (HIMS) stock - MSN
Hims & Hers Health, Inc. (HIMS) suffers a larger drop than the general market: Key insights - MSN
Insider Sell: Irene Becklund Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance
Hims & Hers Health Faces Another Legal Setback Amid Probes and Falling Shares - StocksToTrade
Insider Selling: Hims & Hers Health (NYSE:HIMS) COO Sells 97,289 Shares of Stock - MarketBeat
Hims & Hers Health (NYSE:HIMS) Insider Sells $136,511.01 in Stock - MarketBeat
Hims & Hers health COO Chi sells $2.4m in shares - Investing.com
Top Healthcare Stocks To Follow TodayMarch 18th - MarketBeat
Hims & Hers Opens Waitlist For $149 Branded Wegovy And Ozempic Via Novo Nordisk Deal - Benzinga
Hims & Hers Opens Up Pre-Launch Waitlist For Ozempic And Wegovy Following Partnership With Novo Nordisk - Stocktwits
Telemedicine company Hims & Hers Health Inc. (NYSE: HIMS) announced that its service platform will expand its product range to include Novo Nordisk's Wegovy® (semaglutide) oral tablets and injections, as well as Ozempic® injections. - Bitget
A New Era of Weight Management is Coming to Hims & Hers - Hims & Hers Newsroom
Greenfield Seitz Capital Management LLC Sells 43,334 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Top 2 S&P 500 Stocks to Watch This Week After Hims & Hers Stock's Surprise Move - Yahoo Finance
Healthcare Stocks To ConsiderMarch 17th - MarketBeat
HIMS Stock: After a 57% Surge, Is It Time to Buy Hims & Hers? - CMC Markets
Hims & Hers Health shares see a dip — What is pressuring the stock - Traders Union
Hims & Hers Health, Inc. Investigated by the Portnoy Law Firm - GlobeNewswire
Aquatic Capital Management LLC Purchases New Stake in Hims & Hers Health, Inc. $HIMS - MarketBeat
Here's Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market - MSN
HIMS: Leerink Partners Raises Price Target to $25.00 | HIMS Stoc - GuruFocus
Hims & Hers Health (NYSE:HIMS) Price Target Raised to $25.00 at Leerink Partners - MarketBeat
Hims And Hers Health Pushes Into Complex Care And Global Growth - Yahoo Finance
HIMS Expands Personalized Digital Healthcare Access and Services - The Globe and Mail
Hims & Hers Health Stock Slips After Surging 50% In A Month - Benzinga
Novo Nordisk & Hims & Hers: Supply Deal for Ozempic and WegovyNews and StatisticsIndexBox - IndexBox - Market Intelligence Platform
What is behind Hims & Hers Health stock's recent drop in value today - Traders Union
Why the Novo Nordisk and Hims & Hers deal is a win for both stocks - MSN
Why the Novo Nordisk and Hims & Hers Deal Is a Win for Both Stocks - Yahoo Finance
Farallon Capital Management LLC Purchases 2,533,271 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims & Hers under fire over copycat weight loss drugs - WNTZ-TV FOX 48
Hims & Hers Health (HIMS) Is Up 57.4% After Renewed Novo Nordisk GLP-1 PartnershipHas The Bull Case Changed? - simplywall.st
Hims & Hers Stock Soars on Strategic Pivot with Novo Nordisk - AD HOC NEWS
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Insider Monkey
Clear Street Group Inc. Invests $87.37 Million in Hims & Hers Health, Inc. $HIMS - MarketBeat
Hims & Hers (HIMS) Soars 57.4% on New Deal - Insider Monkey
Hims Hers Health Inc Azioni (HIMS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
1.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):